Rubius Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Depreciation and amortization expense
Change in fair value of preferred stock warrant liability
Amortization (accretion) of premium (discount) on investments
Non-cash interest expense
Impairment charges
Gain on debt extinguishment
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Operating lease, right-of-use-asset
Other assets
Accounts payable
Accrued expenses and other current liabilities
Deferred rent
Other long-term liabilities
Operating lease liabilities

Net cash used in operating activities

Cash flows from investing activities:
Purchases of property, plant and equipment
Proceeds from sale of property, plant and equipment
Purchases of investments
Sales and maturities of investments
Net cash provided by investing activities
Cash flows from financing activities:
Proceeds from issuance of convertible preferred stock, net of issuance costs
Proceeds from underwritten public offering of common stock, net of commissions and underwriting discounts
Payments of offering costs
Proceeds from repayment of promissory note
Payments of debt issuance costs
Proceeds from borrowings under loan and security agreement
Payment of long-term debt
Proceeds from issuance of common stock upon exercise of stock options and under employee stock purchase plan
Net cash provided by (used in) financing activities

Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental cash flow information:
Cash paid for interest
Cash paid for leases
Supplemental disclosure of non-cash investing and financing information:
Purchases of property, plant and equipment included in accounts payable or accrued expenses
Amounts capitalized under build-to-suit lease transaction
Offering costs included in accounts payable and accrued expenses
Lease assets obtained in exchange for new operating lease liabilities
Lease asset derecognized upon lease cancellation
Remeasurement of operating lease liabilities and right-of-use assets due to lease modification
Reclassification of warrant liability to additional paid-in capital
Conversion of preferred stock to common stock upon closing of the initial public offering
Debt issuance costs included in accounts payable and accrued expenses

Comments